更新于：2024-04-01

Small Cell Carcinoma

小细胞癌

更新于：2024-04-01

基本信息

别名

Carcinoma, Oat Cell、Carcinoma, Small Cell、Carcinomas, Oat Cell

+ [40]

简介

An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)

关联

项与小细胞癌相关的药物

Nibrozetone

靶点

CD47 x NLRP3 x c-Myc

作用机制

CD47抑制剂 [+2]

在研机构

EpicentRx, Inc. [+1]

原研机构

EPICENTRE Biotechnologies LLC

在研适应症

小细胞肺癌 [+5]

非在研适应症

晚期胆道癌 [+13]

最高研发阶段临床3期

首次获批国家/地区-

首次获批日期1800-01-20

Vosaroxin

伏利拉辛

靶点

Top II

作用机制

Top II抑制剂

在研机构

National Cancer Institute [+1]

原研机构

Sumitomo Pharma Co., Ltd.

在研适应症

急性髓性白血病

非在研适应症

急性疾病 [+13]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

Nivatrotamab

靶点

CD3 x GD2

作用机制

CD3调节剂 [+1]

在研机构

Memorial Sloan Kettering Cancer Center [+1]

原研机构

Memorial Sloan Kettering Cancer Center

在研适应症

神经母细胞瘤 [+1]

非在研适应症

尤文肉瘤 [+3]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

131

项与小细胞癌相关的临床试验

NCT06161532 / Not yet recruiting临床2期IIT

A Phase II Study of Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer

Background:
Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments. Two drugs-sacituzumab govitecan (SG) and atezolizumab-are each approved to treat other cancers. Researchers want to find out if the two drugs used together can help people with GU.
Objective:
To test SG, either alone or combined with atezolizumab, in people with rare GU tumors.
Eligibility:
Adults aged 18 years and older with rare GU tumors. These may include small cell carcinoma of the bladder; squamous cell carcinoma of the bladder; primary adenocarcinoma of the bladder; renal medullary carcinoma; or squamous cell carcinoma of the penis.
Design:
Participants will be screened. They will have a physical exam with blood and urine tests. They will have tests of heart function. They will have imaging scans. They may need a biopsy: A small needle will be used to remove a sample of tissue from the tumor.
Both SG and atezolizumab are given through a tube attached to a needle inserted into a vein in the arm.
All participants will receive SG on days 1 and 8 of each 21-day treatment cycle. Some participants will also receive atezolizumab on day 1 of each cycle.
Blood and urine tests, imaging scans, and other exams will be repeated during study visits.
Treatment may continue for up to 5 years.
Follow-up visits will continue for 5 more years.

开始日期2024-04-03

申办/合作机构

National Cancer Institute

NCT06228066 / Not yet recruiting临床2期IIT

A Phase II Study of Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)

Background:
Small cell carcinoma of the bladder (SCCB) and other high-grade neuroendocrine tumors (HGNET) of the urinary tract are rare but aggressive cancers. Average survival for people diagnosed with SCCB or HGNET is about 1 year. Lurbinectedin and avelumab are drugs that are approved to treat other cancers. Researchers want to see if these drugs can help people with SCCB or HGNET.
Objective:
To test lurbinectedin with or without avelumab in people with SCCB or HGNET.
Eligibility:
Adults aged 18 years and older with SCBB or HGNET that returned and spread after treatment.
Design:
Participants will be screened. They will have a physical exam. They will have blood tests and imaging scans. They may need to have a new biopsy: A small needle will be used to collect a tissue sample from the tumor.
Both study drugs are given through a tube attached to a needle inserted into a vein. If participants have already received a drug like avelumab they will receive only lurbinectedin. If patients have not been previously treated with a drug like avelumab they will receive both lurbinectedin and avelumab. All participants will receive their treatment once every 3 weeks for up to 10 years. They will also receive other drugs to relieve adverse effects.
Biopsies, blood tests, and imaging scans will be repeated during some study visits. Participants may also have urine tests and tests of their heart function.
Participants may remain in the study as long as the treatment is helping them. If they stop treatment, they will have safety visits 14, 30, and 90 days after their last dose. Additional follow-up visits will continue 5 to 10 years.

开始日期2024-04-03

申办/合作机构

National Cancer Institute

NCT05500391 / Recruiting临床2期

Randomized Phase II Trial Evaluating Compliance With Monitoring Conducted Either by a Hospital-based Physician in Person or by a Nurse in Remote Monitoring

This is a multicenter, interventional, randomized study among adult patients recently diagnosed with a rare tumor (<12 months). The study will aim to compare compliance with the personalized post-treatment surveillance plan, established for each patient according to national guidelines, when the surveillance is conducted in person by a hospital-based physician (control arm) or remotely by a trained nurse (experimental arm).

开始日期2024-02-28

申办/合作机构

Centre Oscar Lambret

100 项与小细胞癌相关的临床结果

登录后查看更多信息

100 项与小细胞癌相关的转化医学

登录后查看更多信息

0 项与小细胞癌相关的专利（医药）

登录后查看更多信息

7,597

项与小细胞癌相关的文献（医药）

2024-02-23·Clinical nuclear medicine

Renal Collision Tumor: A Case of Small Cell Lung Cancer Metastasis to Renal Angiomyolipoma.

Article

作者: Aparna Singh ; Hina J Shah ; Borna E Dabiri ; Wendy Landman

ABSTRACT:

A 68-year-old woman presented with chest pain and shortness of breath. Imaging revealed a left hilar mass biopsy-proven as small cell cancer. Concurrently, a macroscopic fat-containing renal lesion consistent with an angiomyolipoma was observed. Systemic therapy achieved stability in the lungs and bones, and palliative radiation targeted the left hilum. However, progressive lung disease and brain metastases necessitated stereotactic radiosurgery for brain lesions. Notably, the renal angiomyolipoma exhibited increased soft tissue component and new focal uptake on FDG PET/CT. Biopsy confirmed metastatic small cell lung cancer within the renal lesion. This case highlights a rare occurrence of a renal collision tumor involving small cell cancer and angiomyolipoma.

2024-02-22·Molecular imaging and radionuclide therapy

¹⁸F-FDG PET/CT Imaging for Treatment Response Assessment of Cardiac Primitive Neuroectodermal Tumor.

Article

作者: Mehmet Emin Mavi ; Murat Fani Bozkurt

Primitive neuroectodermal tumors (PNETs) are rare and aggressive members of the small round cell carcinoma family. Generally, PNETs are classified into two main groups: PNETs of the central nervous system and PNETs of the peripheral nervous system. Herein, we report the therapy response assessment of a rare case of isolated cardiac PNET using ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) imaging. Given that physiological cardiac FDG uptake is typically observed, assessing FDG avid lesions in the myocardium presents a challenge for FDG PET/CT. This case holds significance because of the rarity of the disease and the challenging nature of the site for FDG PET/CT imaging.

2024-02-22·Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc

Orofacial masses in domestic rabbits: a retrospective review of 120 cases from 2 institutions, 2000-2023.

Article

作者: Emily Rätsep ; Latasha Ludwig ; Melanie Dobromylskyj

Orofacial masses or swellings are a common presenting complaint in lagomorphs. Similar gross appearances of the masses can complicate clinical interpretation, and histologic review often provides the final diagnosis. Underlying causes vary from infectious to neoplastic. Although inflammatory changes are most commonly reported, various neoplasms occur, although the prevalence of specific tumor types is relatively unknown. We reviewed retrospectively 120 cases (87.5% biopsy, 12.5% autopsy) of neoplastic and non-neoplastic orofacial masses received from January 2000-February 2023 at 2 institutions: University of Guelph, Canada (Animal Health Laboratory and Department of Pathobiology), and Finn Pathologists, United Kingdom. All final diagnoses were achieved through histologic assessment. We included masses or mass-like swellings from the oral cavity, including the mandible and maxilla, and surrounding skin and soft tissues of the oral cavity and jaw. Submissions included pet and commercial (meat and fur) rabbits. Neoplastic lesions were most common (60%), including trichoblastomas, papillomas, melanocytic neoplasms, sarcomas, round-cell tumors, carcinomas (including squamous cell carcinoma), lipomas, odontogenic neoplasms, polyps, osteoma, neuroma, peripheral keratinizing ameloblastoma, and apocrine adenoma. Inflammatory diagnoses (30%) included abscesses, osteomyelitis, dermatitis, and sialadenitis. Other diagnoses (7%) included cysts, as well as hyperplastic skin and proliferative bone lesions. Three cases had no definitive diagnosis. The importance of histologic assessment in diagnosing orofacial "masses" in rabbits is highlighted, given that the most common diagnostic category overall was neoplasia.

375

项与小细胞癌相关的新闻（医药）

2024-03-11

·贝达

贝达药业盐酸恩沙替尼美国申报上市获FDA受理

3月12 日，贝达药业与美国控股子公司Xcovery收到美国食品药品监督管理局（FDA）的受理信，公司提交的盐酸恩沙替尼（以下简称“恩沙替尼”）,拟用于间变性淋巴瘤激酶（ALK）阳性的局部晚期或转移性非小细胞肺癌（NSCLC）患者的治疗”（即一线适应症）上市许可申请获得了FDA正式受理，进入实质性审查阶段，标志着恩沙替尼海外上市的重要一步。该产品于2020年已在中国获批上市。肺癌是世界上常见的恶性肿瘤之一,同时也是中国恶性肿瘤发病和死亡的首位原因。肺癌包括非小细胞肺癌（NSCLC）和小细胞肺癌（SCLC），非小细胞肺癌约占肺癌的80%-85%，与小细胞癌相比，其癌细胞生长分裂较慢,扩散转移相对较晚，约75%的患者发现时已处于中晚期，5年生存率很低。间变性淋巴瘤激酶（ALK）是非小细胞肺癌重要的致癌驱动因子之一，ALK融合蛋白基因在NSCLC患者中的阳性率为5%左右，且多见于年轻、不吸烟或轻度吸烟的肺腺癌患者。ALK激活之后能够导致下游信号通路被激活，进而引发肿瘤的发生和生长，ALK抑制剂能够有效抑制ALK的活性，从而起到抑制肿瘤生长的作用。恩沙替尼是贝达药业与Xcovery共同开发的拥有完全自主知识产权的全新化学结构、新型强效、高选择性的新一代ALK抑制剂。本次顺利申报NDA是贝达药业继2021年12月在美国成功申报首个IND后尝试国际化迈出更重要的一步，恩沙替尼有望成为首个由中国企业主导在全球上市的肺癌靶向创新药。 Xcovery 首席执行官桑凌表示：“恩沙替尼在国内上市以来，造福国内肺癌患者，创造了良好的经济和社会效益。作为贝达的首个海外NDA项目，后续我们将积极配合美国FDA的审计核查，争取早日取得最后的通行证。” 贝达药业董事长丁列明博士表示：“此次FDA的正式受理，是贝达药业走向海外的重要一步，期待恩沙替尼能够早日在美获批上市，为全球患者提供新的用药选择，加速推动公司的国际化发展，增加开拓海外更多潜在市场的可能性。”

临床申请

2024-02-23

·奇点网

《科学》：找到烟民专属防肺癌免疫遗传特征！西奈山伊坎医学院团队发现，HLA-II基因座杂合性可降低吸烟者肺癌风险

*仅供医学专业人士阅读参考众所周知，吸烟是肺癌最主要的诱因。吸烟可以通过DNA损伤等机制导致肺癌，8成以上肺癌死亡由吸烟导致。也有一些“天赋异禀”的人，烟抽着身体还倍儿棒。不得不说大自然还是很讲究平衡的，面对吸烟的风险，人体也存在抵抗风险的机制。本周，博德研究所和西奈山伊坎医学院的科研人员在《科学》杂志发表论文，研究者们发现了一个烟民“专属”的保护性免疫特征，人类白细胞抗原（HLA）-II基因座杂合性。这意味着免疫监视系统中的遗传变异与环境暴露、遗传风险、DNA复制缺陷等因素一样，也是癌症易感性的特征之一。同时这也证实，人类的免疫系统就像防御病原体感染那样，同样在防御癌症的发生。当然，没有让烟民放心的意思，因为就算有了专属抗癌免疫特征，风险还是比不抽烟的人高多了啊哈哈论文题图免疫监视假说认为，淋巴细胞会不断地在组织中寻找存在突变导致的新抗原的肿瘤细胞，这能有效地触发免疫反应、消除发展中的癌症。不过免疫系统到底能不能像预防病原体那样预防癌症，其实一直都有争议。免疫系统如何影响癌症发生？有GWAS研究发现，涉及HLA的个体单核苷酸多态性（SNP）和HLA-1/2等位基因与肺癌易感性之间存在关联。HLA是一组高度多态性的基因，它编码的主要组织相容性复合体（MHC）是抗原递呈和识别的关键。生物进化中有杂合子优势假说。依据这个理论，杂合HLA应当能够为T细胞识别提供更多的抗原，从而更有效地清除感染细胞或癌细胞，从而带来更强的疾病保护作用。那么事实是否如此呢？在本项研究中，研究者们假设杂合HLA基因与肺癌风险降低有关。为了验证这一假设，研究者们调取了两个大型人群队列的数据，英国生物库UK Biobank（N=391182）和芬兰FinnGen（N=183163），综合分析单细胞RNA测序数据和肺基因组图谱，试图寻找HLA介导的肺癌保护机制。这两个数据库都拥有较为完整的个体水平的遗传、环境和临床纵向数据，包括HLA基因型的数据。研究的主要终点为首次诊断或因肺癌死亡，随访时间约14年。研究者在英国生物库筛选到了2468名符合标准的肺癌患者，其余人（N=384928）作为对照组。与其他研究报道一致，腺癌是最常见的组织学亚型（N=700），鳞状细胞癌（N=338）和小细胞癌（N=192）次之。肺癌患者中86.8%吸烟或曾经吸烟，性别大致均等。FinnGen中筛选到3480名肺癌患者，亚型分布与英国生物库基本一致。不过差别在于吸烟者比例不同，FinnGen中有70.8%肺癌患者正在吸烟，英国生物库中比例则为41.8%；FinnGen中男性肺癌患者吸烟的比例也远高于女性患者（78.3% vs 21.7%），英国生物库中则更为平均。两个队列中除了HLA-DQA1之外，其他HLA等位基因频率基本一致，具有可比性。分析结果显示，相对肺癌患者，对照组的HLA-II杂合性显著更高，说明它确实与肺癌风险降低有关。有趣的是，5个HLA-II基因的单独杂合度和所有基因的最大杂合度都具有保护作用，但是这并不表现在HLA-I基因上。HLA基因杂合对肺癌风险的影响研究者进一步分析了HLA基因座杂合性在更长时间尺度上对肺癌发生的影响。如同预期，当前吸烟者患肺癌的风险最高，其次是已经戒烟者，而在这两组人中可以观察到HLA-II杂合具有显著的保护效果，非吸烟者却没有享受到这种“福利”。反之，纯合HLA-II则带来相当大的终生患病风险，例如英国生物库中，纯合HLA-DRB1当前吸烟者终生患肺癌风险为13.9%，杂合HLA-DRB1者则为10.8%。HLA-II杂合是烟民专属的保护伞不同HLA-II杂合的保护效果对邻近正常肺细胞的单细胞RNA测序显示，吸烟会导致肺泡巨噬细胞中的HLA-II和促炎通路的上调。研究者分析了癌症基因组图谱（TCDA）、泛癌全基因组分析（PCAWG）和Hartwig医学基金会队列的数据，证实肺癌中存在普遍的HLA-II杂合性丢失（LOH），这会更有利于癌细胞的免疫逃逸。以上发现可以证实，免疫监视中的遗传变异与环境暴露、遗传风险和DNA复制缺陷同样，是癌症易感性的关键特征。这拓展了对宿主免疫系统在癌症风险中作用的理解，免疫遗传学也可能成为癌症筛查的关键。参考资料：[1]https://www.science.org/doi/10.1126/science.adi3808[2]https://medicalxpress.com/news/2024-02-reveals-insights-immune-role-lung.html本文作者丨代丝雨

临床结果临床研究

2024-02-12

·Business Wire

Prostate Cancer Prevention and Treatment Technologies: Comprehensive Global Market Analysis - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for prostate cancer care reached $35.3 billion in 2022. This market is expected to reach $56.4 billion by the end of 2028, growing at a CAGR of 8.3% from 2023 through 2028. As the second most diagnosed male cancer in the world, prostate cancer affects roughly 1.4 million people and kills more than 370,000 men each year, which represents about 4% of all cancer deaths worldwide. This cancer ranges from being a non-aggressive, slow-growing type that can do without treatment to an aggressive, fast-growing disease that needs intervention and timely treatment. Hence, early detection/screening, diagnosis and staging of prostate cancer are critical. The global market for prostate cancer screening and detection is projected to grow at a CAGR of 5.8% to reach $19.8 billion by the end of 2028. It is estimated that over 60% of age-eligible men remain unscreened for prostate cancer. A large, underserved population of unscreened and inadequately screened patients represents a significant opportunity for non-invasive biomarker tests in the prostate cancer screening market. The global market for prostate cancer pharmaceuticals was valued at $16.0 billion in 2022 and is expected to reach $29.6 billion by the end of 2028, at a CAGR of 11.0% during the forecast period. Continued incidence of prostate cancer, the world's growing elderly population, and increasing therapeutic innovations are key driving factors in the market for prostate cancer drugs. The direct cost for radical prostatectomy was estimated at $3.6 billion in 2022. This cost is expected to rise to $4.8 billion by the end of 2028. The growing popularity of robot-assisted laparoscopic prostatectomy (RALP) is expected to impact the overall radical prostatectomy market. Improved screening programs will result in an increase in radical prostatectomies, as this procedure is preferred in early detection stages. The radiotherapy device market is expected to grow as the incidence of prostate cancer worldwide continues to increase and better and more accurate imaging technologies combined with precise treatment strategies are developed. This market is expected to reach $2.2 billion by the end of 2028. This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report. The Report Includes 31 data tables and 63 additional tables An overview of the global market for the technologies for prevention and treatment of prostate cancer Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028 Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies Profiles of leading market participants Key Attributes: Report Attribute Details No. of Pages 157 Forecast Period 2023 - 2028 Estimated Market Value (USD) in 2023 $37.9 Billion Forecasted Market Value (USD) by 2028 $56.4 Billion Compound Annual Growth Rate 8.3% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market Overview Prostate Cancer Biology of Prostate Cancer Symptoms Screening Diagnosis Localized Prostate Cancer Metastatic Prostate Cancer Watchful Waiting or Active Surveillance Treatment Chapter 4 Market Dynamics Market Drivers Increasing Prevalence of Prostate Cancer Active Surveillance and Screening Personalized Care Approvals for Metastatic Castration-Resistant Prostate Cancer Collaborations and Licensing Agreements Market Challenges Loss of Exclusivity and Genericization Shortage of Care Providers and Other Resources Market Opportunities Chapter 5 Screening and Diagnosis Market by Test Type Biomarker Tests PSA Tests Limitations of PSA Tests Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings Digital Rectal Exam Limitations of DREs Prostate Biopsy Grade (Gleason Score) of Prostate Cancer Prostatic Intraepithelial Neoplasia Atypical Small Acinar Proliferation Proliferative Inflammatory Atrophy Intraductal Carcinoma of the Prostate Limitations of Prostate Biopsies Imaging Technologies for Prostate Cancer Market for Prostate Cancer Screening/Diagnosis, by Test Type Biomarker Tests DREs Prostate Biopsies Chapter 6 Pharmaceuticals Market by Drug Type Hormone Therapy Androgen Deprivation Therapy Antiandrogen Therapies Hormone Therapy Uses in Prostate Cancer Treatment Targeted Therapy PARP Inhibitors Radioligand Therapies Small Molecule Targeted Agents Monoclonal Antibodies Chemotherapy Immunotherapy Market Revenue, by Drug Type Hormone Therapy Targeted Therapy Immunotherapy Chemotherapy Chapter 7 Market for Surgery and Radiation Therapy by Treatment Type Active Surveillance Radical Prostatectomy Robotic Prostatectomy Open Radical Prostatectomy Laparoscopic Prostatectomy Radical Prostatectomy Market Revenue Radiation Therapy External Beam Radiation Therapy Brachytherapy Combined Radiation Therapy Radiation Therapy Device Market Revenue Chapter 8 Market Breakdown by Region Chapter 9 Emerging Technologies and Developments Liquid Biopsy Multiparametric MRI Homologous Recombination Repair Gene Mutation Advanced Radiotherapy Techniques AI and Machine Learning Chapter 10 Pipeline Analysis Chapter 11 Competitive Intelligence Screening and Diagnosis Market Market for Radiation Therapy Devices Pharmaceuticals Market Chapter 12 Company Profiles Abbott Accuray Astellas Pharma Astrazeneca Bayer Danaher Corp. Dendreon Pharmaceuticals Elekta F. Hoffmann-La Roche Johnson & Johnson Services Pfizer Sanofi Siemens Healthineers For more information about this report visit https://www.researchandmarkets.com/r/wra8q3 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

放射疗法